16.ALPHA.-FLUOROESTRADIOL
Ductal Breast Carcinoma In Situ
Explore 23 assets in Ductal Breast Carcinoma In Situ →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
University of Wisconsin, Madison
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ductal Breast Carcinoma In Situ
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 16.ALPHA.-FLUOROESTRADIOL (this asset) | University of Wisconsin, Madison | P2 | CCC · 48 |
| Ropivacaine | Zealand University Hospital | P4 | BB |
| Sufentanyl | Zealand University Hospital | P4 | BB |
| Tamoxifen | National Cancer Institute (NCI) | P3 | BB |
| Anastrozole | Alliance for Clinical Trials in Oncology | P3 | BB |
| (Z)-Endoxifen | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) | P2 | BB |
| Letrozole | Alliance for Clinical Trials in Oncology | P3 | BB |
| Oxybutynin | Academic and Community Cancer Research United | P3 | BB |
| Metformin | M.D. Anderson Cancer Center | P3 | BB |
+42 more in the Ductal Breast Carcinoma In Situ cohort
Other indications for 16.ALPHA.-FLUOROESTRADIOL
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | B · 56 |
| Estrogen-Receptor Positive Breast Cancer | — | P2 | CCC · 49 |
| Breast Neoplasm | — | P2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 16.ALPHA.-FLUOROESTRADIOL in Ductal Breast Carcinoma In Situ. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/16alpha-fluoroestradiol-ductal-breast-carcinoma-in-situ
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →